Cypre Platform
A 3D tumor model platform that recreates the tumor-stromal-immune microenvironment to support therapeutic development through IND. Built for mechanism of action studies, biomarker discovery, and predictive preclinical data.
The Foundation of Translationally Relevant Preclinical Insights
Let's PartnerPlatform Capabilities
3-Tiered Models: Integrated tumor, stroma, and immune cells for evaluating microenvironment interplay
MOA & Immune Analytics: High-content imaging, multiplex cytokine profiling, and flow cytometry
RNA-Seq Enabled: Multi-omic analyses correlating phenotypic outcomes with transcriptional signatures
IND-Ready Outputs: Standardized data packages aligned with regulatory expectations
MOA & Immune Analytics: High-content imaging, multiplex cytokine profiling, and flow cytometry
RNA-Seq Enabled: Multi-omic analyses correlating phenotypic outcomes with transcriptional signatures
IND-Ready Outputs: Standardized data packages aligned with regulatory expectations
Partner Applications
- Identify and validate novel targets using TME-contextualized screening
- Validate mechanisms for bispecifics, ADCs, and immune-modulating agents
- Generate preclinical biomarker hypotheses
- Explore responder vs. non-responder profiles for patient stratification
- Evaluate indication expansion or lead differentiation
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
MOA Analytics for Immunotherapy
Representative readouts from NSCLC model treated with a T cell engager: CD45+ infiltration via immunofluorescence, T cell activation panel via flow cytometry, and multi-plex cytokine profiling.
Request Full Data Overview
Transformative Technology for Collaborative Oncology Development
Cypre’s 3D organoid platform is purpose-built to empower partners with a more predictive, human-relevant approach to cancer drug discovery. Engineered using our proprietary VersaGel® hydrogel technology, this platform reconstructs the human tumor microenvironment, capturing essential tumor, stromal, and immune interactions that standard preclinical models miss.
The Cypre Platform enables partners to explore mechanism of action, evaluate immune dynamics, stromal modulation, and generate biomarker-driven insights, all within a high-throughput, reproducible framework. Our robust, decision-grade data package streamlines the path from discovery to IND.
The Cypre Platform enables partners to explore mechanism of action, evaluate immune dynamics, stromal modulation, and generate biomarker-driven insights, all within a high-throughput, reproducible framework. Our robust, decision-grade data package streamlines the path from discovery to IND.
Testimonials
“We work with Cypre to access their unique 3D tumor models and have found interesting insights into modeling the tumor microenvironment. We look forward to increasing our utilization of the Cypre platform for our future projects.”
Top Pharma
Drug Discovery Director
"The Cypre platform enabled us to efficiently screen IC50s across different tumor types, giving us critical antitumor data that supported the formation of a startup company."
Brown University
Professor of Oncology
Ready to Explore a Partnership?
Fill out the form to connect with our business development team and learn how Cypre’s advanced tumor modeling platform can support your program. We’ll walk you through the technology, discuss your objectives, and explore how we can collaborate to drive smarter oncology development.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Let’s Build the Future of Oncology, Together
Partner with Cypre to co-develop translationally validated, IND-ready insights using our complete 3D tumor organoid platform. From immune profiling to tailored study designs, we’re built for collaboration.
© Cypre Inc. All rights reserved.